Controlled release pharmaceutical dosage forms, methods of making the same, and methods of using the same to treat dermatological conditions are disclosed. A doxycycline formulation that is retained and released in a controlled manner in the upper portion of the gastrointestinal tract. The formulation provides enhanced efficacy and reduced side effects and/or adverse effects when compared to conventional immediate release dosage forms of doxycydine. Although delaying the release of doxycycline has previously been reported to decrease doxycycline's oral bioavailability, it has now been surprisingly found that when administered in a controlled release fashion, the relative oral bioavailability when compared to immediate release formulation of doxycycline was more than about 80% and in certain embodiments, more than about 90% orally bioavailable.
